Kevin Chaplin
CanadaCEOMale8.0Global Dominance: 0.00%Kevin Chaplin is the CEO of Kardium Inc., a Vancouver-based medical device company specializing in innovative treatments for atrial fibrillation. Under his leadership, Kardium has developed a groundbreaking pulsed field ablation technology and recently raised $340 million to prepare for FDA approval and market entry.
Power3,014
Reach67,385
Country presence
Recent news mentions
Kevin Chaplin, Kardium’s chief executive officer, discussed the advancements of their medical device for treating atrial fibrillation.
Kardium receives Health Canada approval to sell device treating common heart problemThe Globe and Mail·Canada· 2026-08-07
Canada· 2026-08-07Kevin Chaplin is the CEO of Kardium, which makes a device for treating atrial fibrillation.
Has Canada’s biotech moment finally arrived?The Globe and Mail·Canada· 2026-08-04
Canada· 2026-08-04
Kevin Chaplin is the CEO of Kardium, which has received FDA approval for its medical device.
Kardium gets FDA greenlight to sell in the U.S. device that treats common heart problemThe Globe and Mail·Canada· 2025-09-03
Canada· 2025-09-03
Kevin Chaplin is the CEO of Kardium and is optimistic about receiving FDA approval for their heart device.
Kardium raises $340-million as B.C. heart device maker prepares for FDA approval, market entryThe Globe and Mail·Canada· 2025-07-02
Canada· 2025-07-02
